Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2009

View Archived Issues

Oral Alequel shows promise in a phase II trial for the treatment of Crohn's disease

Sarcoma treatment snapshots from ASCO

Forest reports results from FOCUS I and II phase III studies of ceftaroline in CABP

Takeda presents novel MEK/ERK inhibitors as oncolytics

Interim data from phase II trials support the potential of SB-509 in diabetic peripheral neuropathy

Diamyd vaccine proven safe and immunogenic in children and adolescents with type 1 diabetes

Improved lean body mass by MK-0773 not associated with hypertrophic prostatic activity

Positive results seen with recombinant measles vaccine in phase I study

Novartis quadrivalent meningococcal vaccine safe and immunogenic in infant population

Merck & Co. and DNDi enter master agreement for neglected tropical diseases

USAN approved generic name of Clinical Data's vilazodone hydrochloride for depression

Biovitrum transfers preclinical GPR-119 and SCD-1 diabetes projects to iNovacia

Biogen Idec enrolls first patient in phase III ADVANCE clinical trial of BIIB-017 in RMS

Cordex Pharma and Clinical Trials International sign license agreement for ATPotent

Prospect Therapeutics to develop GCS-100 for blood-borne cancers

Pharmexa issues consideration shares to Affitech shareholders under merger agreement

UCL/M initiates next step in phase I/II clinical trial of Targeted Genetics' AAV-RPE65 in LCA

GTx Inc. describes estrogen receptor-beta agonist for obesity treatment

Bayer Schering Pharma claims novel PAR-1 antagonists

Shanghai Hengrui discovers novel CETP inhibitors for the treatment of lipoprotein disorders

Takeda initiates phase III clinical trial of hypertension drug TAK-536 in Japan

Enzon initiates phase II trial of cancer drug PEG-SN38 in metastatic colon cancer

FDA approves Cambia for acute migraine with or without aura in adults

Wyeth extends research period under 2005 collaboration agreement with Trubion

Provectus initiates compassionate-use program in Australia for PV-10 in cancer

RegeneRx and U.S. military to test TB4 against exposure to chemical agents in the eye

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.